agrees guidant deal
pharmaceutical giant johnson johnson agreed buy medical technology firm guidant
guidant key producer equipment combats heart implant defibrillators pacemakers analysts deal aimed offsetting johnson johnson reliance slowing drug business mergers drug healthcare industries fragmented pressure cut costs johnson johnson products facing patent expirations company battling fierce competition generic products demand defibrillators heart electric shock irregular heartbeat rhythm detected expected increase analysts move johnson johnson expected firm pay guidant share wednesday closing price analysts antitrust regulators force firms overlapping stent operations stents tubes artery unblocked
